Artificial intelligence (AI) is compressing parts of drug discovery from years into, in some cases, minutes. The regulatory clock has not sped up to match.
That gap is where biotech investors win or lose. A lab breakthrough is still only a candidate until it clears human trials overseen by the U.S. Food and Drug Administration (FDA), and small biotech stocks tend to trade on where a drug sits in that process rather than how exciting the science sounds.
.png?w=600)
